The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here are three stocks where Wall Street’s estimates seem disconnected from reality and some better opportunities to consider.
The Real Brokerage (REAX)
Consensus Price Target: $5.15 (189% implied return)
Founded in Toronto, Canada in 2014, The Real Brokerage (NASDAQ: REAX) is a technology-driven real estate brokerage firm combining a tech-centric model with an agent-centric philosophy.
Why Do We Pass on REAX?
- Subpar operating margin of -0.6% constrains its ability to invest in process improvements or effectively respond to new competitive threats
- Earnings per share lagged its peers over the last four years as they only grew by 8.5% annually
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
At $1.78 per share, The Real Brokerage trades at 0.2x trailing 12-month price-to-sales. If you’re considering REAX for your portfolio, see our FREE research report to learn more.
Supernus Pharmaceuticals (SUPN)
Consensus Price Target: $62.83 (41.6% implied return)
With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ: SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.
Why Does SUPN Fall Short?
- Muted 5.9% annual revenue growth over the last five years shows its demand lagged behind its healthcare peers
- Smaller revenue base of $776.9 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
Supernus Pharmaceuticals’s stock price of $44.38 implies a valuation ratio of 2.8x forward price-to-sales. Dive into our free research report to see why there are better opportunities than SUPN.
Collegium Pharmaceutical (COLL)
Consensus Price Target: $54.33 (62.1% implied return)
Pioneering abuse-deterrent technology in a field plagued by addiction concerns, Collegium Pharmaceutical (NASDAQ: COLL) develops and markets specialty medications for treating moderate to severe pain, including abuse-deterrent opioid formulations.
Why Do We Think Twice About COLL?
- Revenue base of $796.3 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Costs have risen faster than its revenue over the last two years, causing its adjusted operating margin to decline by 6.4 percentage points
- ROIC hasn’t moved, making investors question whether its recent investments can increase profitability
Collegium Pharmaceutical is trading at $33.53 per share, or 1.5x forward price-to-sales. Check out our free in-depth research report to learn more about why COLL doesn’t pass our bar.
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
